Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02093611 · ClinicalTrials.gov registry record · NA

Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout

A NA study, sponsored by Metabolic Technologies.

Completed
Registry status
NA
Development phase
42
Enrollment target

NCT02093611: Completed NA study, sponsored by Metabolic Technologies.

NCT02093611 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02093611, a NA study, has completed, sponsored by Metabolic Technologies.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target

Study Summary

We hypothesize that adenosine-5'-triphosphate (ATP) supplementation will be able to enhance motor unit recruitment while simultaneously blunting the decline in power and reaction time that is typically seen during repetitive sprints. This will give researchers a better understanding of the mechanism by which ATP supplementation can augment power, especially under high fatiguing conditions.

Primary Outcome

Muscle excitability will be measured using Delsys Wireless Electromyography (EMG) sensors.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT ATP

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2013-07
Est. Completion 2015-08
Phase NA
Metabolic Technologies

16 total trials

What the finished NCT02093611 record still lists

NCT02093611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02093611 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02093611 about?

NCT02093611 is a clinical study titled "Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout". We hypothesize that adenosine-5'-triphosphate (ATP) supplementation will be able to enhance motor unit recruitment while simultaneously blunting the decline in power and reaction time that is typically seen during repetitive sprints. This will give researchers a better understanding of the mechanism...

What is the current status of trial NCT02093611?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2013-07. Estimated completion is 2015-08.

What interventions are being tested in trial NCT02093611?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), ATP (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02093611?

This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02093611's enrollment target sits among peer trials

42 1436th of 2000 higher than 555 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02093611, the US trial registry maintained by the National Library of Medicine. NCT02093611 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.